Crucell Signs Commercial PER.C6 License Agreement With SingVax
company Crucell N.V. today announced the signing of a commercial
PER.C6 license agreement with Singapore-based company SingVax Pte Ltd
development and commercialization of new vaccines against Japanese
Under the agreement, SingVax will focus on the development and
of a Japanese encephalitis vaccine for the endemic population as well
travelers to the Asia Pacific region.